Key takeaway
What This Development Means
A California complaint alleges that repeated use of menstrual, intimate-care and incontinence products exposed seven women to PFAS and other substances without adequate warnings. The allegations remain unproven.
What Should Intimate-Care Businesses Review?
Companies should assess supplier data, analytical testing methods, contamination controls and evidence supporting safety or "clean" claims. Reviews should cover ingredients, materials, coatings, packaging and manufacturing processes while distinguishing confirmed findings from assumptions based on product category.
Does The Lawsuit Prove That PFAS Caused The Reported Injuries?
No. The complaint sets out the plaintiffs' allegations, not judicial findings. Liability would require evidence concerning product composition, exposure, dose, medical causation, warnings and each defendant's conduct. Detecting PFAS alone would not prove that a product caused a particular condition.
PFAS litigation is deepening its reach into intimate-care and personal-care categories, where purchasing decisions depend heavily on confidence in product safety. Seven California women have sued major hygiene businesses, alleging that repeated use of menstrual, intimate-care and incontinence products exposed them to PFAS and other substances without adequate warnings.
The complaint began in Los Angeles Superior Court and was removed to the US District Court for the Central District of California on 9 July 2026. Defendants include Procter & Gamble, Kimberly-Clark, Prestige Consumer Healthcare, Edgewell Personal Care, Essity North America, The Honey Pot Company and associated entities. The claims are allegations and have not been proven.
PFAS Claims Target Trust-Sensitive Products
The plaintiffs identify tampons, pads, feminine washes, wipes, menstrual underwear, deodorising sprays and women's incontinence products. They allege exposure to PFAS, endocrine-disrupting chemicals, volatile organic compounds, heavy metals, fragrances and preservatives contributed to reproductive and gynaecological injuries.
The filing does not provide independent laboratory results establishing that each named product contained these substances or proving that particular exposures caused the plaintiffs' conditions. Its allegations will need to be tested through evidence, expert testimony and the court process.
This is not the first litigation involving PFAS allegations in menstrual products. A 2024 California Proposition 65 action targeted Carefree liners, while earlier consumer claims challenged PFAS-related marketing for period underwear and tampons. The latest case therefore indicates an expansion of an existing litigation theme rather than its first entry into intimate care.
Personal-Care Supply Chains Face Wider Exposure
The complaint advances eight causes of action, including failure to warn, design defect, negligence, breach of warranty, fraud and fraudulent concealment. It seeks compensatory and punitive damages and requests a jury trial.
For brand owners, formulators, raw-material suppliers, laboratories, contract manufacturers and retailers, the commercial risk extends beyond liability. Claims such as "clean", "natural", "organic", "gentle" and "pH-balanced" may attract scrutiny when consumers interpret them as assurances about chemical composition.
Research has detected PFAS or fluorine indicators in some menstrual and personal-care products, although detection does not by itself establish exposure, dose or causation of a specific illness.
Summary
The lawsuit shows PFAS litigation extending further across intimate-care categories, where safety claims carry exceptional reputational weight. Although the allegations remain unproven, businesses should examine testing, supplier declarations, traceability and marketing substantiation to reduce legal exposure and protect consumer confidence.
Related Articles
PFAS Liability Expands As New York Targets Statewide Cleanup And Consumer Warnings
New York's lawsuit broadens PFAS exposure across environmental cleanup, consumer protection, warnings and product stewardship.
Estee Lauder Fined $750,000 Over PFAS Cosmetics CEPA Violations
Enforcement action under CEPA highlights compliance expectations when PFAS substances trigger significant new activity notification requirements.
New Jersey PFAS Restrictions Expand Under Protecting Against Forever Chemicals Act
New Jersey’s Forever Chemicals Act bans intentionally added PFAS in key consumer products and introduces mandatory cookware labelling.
